WO2000064444A1 - Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines - Google Patents
Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines Download PDFInfo
- Publication number
- WO2000064444A1 WO2000064444A1 PCT/FR2000/001099 FR0001099W WO0064444A1 WO 2000064444 A1 WO2000064444 A1 WO 2000064444A1 FR 0001099 W FR0001099 W FR 0001099W WO 0064444 A1 WO0064444 A1 WO 0064444A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- isoxazole
- derivative
- aminotetralin
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Definitions
- the present invention relates to new pharmaceutical compositions comprising derivatives of 2-isoxazoles-8-aminotetralins.
- compositions could be used for topical administration comprising a derivative of 2-isoxazole-8-aminotetraline.
- an adhesive polymer system or "patch", term of English origin
- the invention therefore relates to a matrix or reservoir pharmaceutical composition for topical administration comprising at least one 2-isoxazole-8-aminotetralin derivative in a therapeutically effective amount and one or more pharmaceutically acceptable excipients.
- 2-isoxazole-8-aminotetralin derivative is meant in particular all those which have been described in the patents cited above.
- Said 2-isoxazole-8-aminotetralin derivative can be in the form of a free base or in the form of a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt means in particular addition salts of inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide and nitrate or organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methane sulfonate, p-toluenesulfonate, pamoate, oxalate and stearate.
- the salts formed from bases such as sodium or potassium hydroxide.
- the 2-isoxazole-8-aminotetralin derivative will be in the form of a pharmaceutically acceptable salt.
- a patch will be used which will contain in its matrix the derivative of 2-isoxazole-8-aminotetralin.
- Said patch can be presented in different forms: reservoir; matrix on adhesive polymer; DIA patch (i.e. "Drugln Adhesive" in English), in other words patch in the form of a single adhesive polymer layer in which the active principle is distributed; or finally multilamellar patch.
- DIA patch i.e. "Drugln Adhesive” in English
- DIA patch i.e. "Drugln Adhesive” in English
- patch in the form of a single adhesive polymer layer in which the active principle is distributed
- multilamellar patch multilamellar patch.
- the excipients can be polymers or copolymers or else simply monomers.
- the composition will incorporate adhesive polymers or copolymers such as elastomers of the polyethylene vinyl acetate (EVA) type, polymers or copolymers based on styrene, polyisobutylene or acrylic polymers or copolymers, and in particular methacrylic copolymers.
- EVA polyethylene vinyl acetate
- plasticizers include, for example, tributylacetyl citrate or any other pharmaceutically acceptable plasticizer known to those of skill in the art.
- a gelling agent is present in a proportion preferably of 20 to 50%.
- the gelling agents which can be used for the topical compositions according to the invention notably comprise the cellulose derivatives, and in particular hydroxypropyl-methyl cellulose (HPMC), or the poloxamers (that is to say copolymers of polyethylene and of propylene glycol), in particular Lutrol ® F 127 (BASF).
- the topical compositions according to the invention can also comprise other excipients in order to facilitate the transdermal passage of the 2-isoxazole-8 derivative.
- aminotetralin in other words transdermal absorption promoters, and in particular alcohols or polyols such as ethanol, 1,3-butanediol, polyethylene glycols (PEG), fatty acid esters, in particular triglycerides of caprylic and capric acids and in particular Miglyol® (H ⁇ ls, Mari, Germany), or other surfactants or amphiphilic substances known to those skilled in the art.
- ethanol or fatty acid esters such as Miglyol® are preferred.
- compositions according to the invention may also comprise, where appropriate and in particular when they are in the form of an aqueous gel, a preservative, preferably propylene glycol. Likewise, they may also include an antioxidant agent, and in particular ethylenediaminetetracetic acid (EDTA).
- a preservative preferably propylene glycol.
- EDTA ethylenediaminetetracetic acid
- a topical pharmaceutical composition according to the invention will preferably comprise between approximately 5 and 80 mg, more preferably between approximately 5 and 50 mg, and more particularly between approximately 5 and 20 mg, for example approximately 5 mg of 2-isoxazole-8 derivative. -aminotetralin, this mass being calculated relative to said derivative in the form of the free base. This dose should make it possible to ensure the daily treatment of a patient, but it is up to the attending physician to decide ultimately how often to apply.
- the pH of the topical pharmaceutical composition according to the invention will preferably be between 7 and 9.5, and more preferably between 8 and 9.5 when the derivative of 2- isoxazole-8-aminotetralin is in the form of the free base.
- the pH of the topical pharmaceutical composition according to the invention will preferably be between 5 and 7.5, and more preferably between 5.5 and 7.
- the invention also relates to the use of a derivative of 2-isoxazole-8-aminotetralin, and in particular of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) -N, N-diisopropyl- 2-naphthalenamine, for the manufacture of a medicament for transdermal administration, in particular in the treatment of irritable bowel syndrome.
- a derivative of 2-isoxazole-8-aminotetralin and in particular of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) -N, N-diisopropyl- 2-naphthalenamine
- a patch intended for the transdermal administration of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) - N, N-diisopropyl-2-naphthalenamine was prepared from a copolymer of methacrylate and ammonioalkyl according to the procedure described below.
- the solution obtained is then spread at a rate of 100 g / m 2 on a carrier sheet (15 ⁇ m thick, Revtrans MN, Tricon GmbH, Freiburg-im-Breisgau, Germany).
- the polymer layer is dried for 10 minutes with a flow of 1500 m 3 / h of air at 60 ° C (recycling with 80 m 3 / h of exhaust).
- the polymer obtained can then be cut to form patches with an area of approximately 15 cm 2 , which can be used to dispense a daily dose.
- a patch intended for the transdermal administration of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) - N, N-diisopropyl-2-naphthalenamine was prepared from a copolymer of methacrylate and of ammonioalkyl according to the mode procedure described in Example 1, except that 10 g of Miglyol® 812 (Huis, Mari, Germany) were added in portions between the addition of 1,2,3,4-tetrahydro-8- (5- isoxazolyl) -N, N-diisopropyl-2-naphthalenamine and the addition of succinic acid and that after this addition of Miglyol® 812, the mixture was stirred for an additional 20 minutes.
- Miglyol® 812 Huis, Mari, Germany
- a patch intended for the transdermal administration of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) - N, N-diisopropyl-2-naphthalenamine was prepared from a copolymer of methacrylate and of ammonioalkyl according to a method procedure similar to that described in Example 1. except that the 20 g of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) -N, N-diisopropyl-2-naphthalenamine are replaced by 22.44 g of 1,2,3,4-tetrahydro- 8- (5-isoxazolyl) -N, N-diisopropyl-2-naphthalenamine hydrochloride.
- a gel intended for the transdermal administration of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) - N, N-diisopropyl-2-naphthalenamine was prepared from an aqueous dispersion of hydroxypropyl -methyl cellulose (HPMC), according to the procedure described below (to prepare 100 g of gel).
- HPMC hydroxypropyl -methyl cellulose
- composition of the gel is composition of the gel:
- solution I An aqueous solution (solution I) is first prepared by dissolving 3 g of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) -N, N-diisopropyl-2-naphthalenamine hydrochloride in 4 g of propylene glycol and 8 g of purified water. The solution thus obtained is then filtered on a 10 ⁇ m filter. We obtain solution I.
- aqueous dispersion of HPMC is then prepared under vacuum by mixing 30 g of HPMC with 55 g of purified water. Still with stirring, the mixture is heated to a temperature of 50-60 ° C., for 20 min, until a gel of homogeneous appearance is obtained (gel II).
- Solution I is added in portions to gel II, then the mixture is left for 20 min still under vacuum, with stirring and at 50-60 ° C, to obtain 100 g of drug.
- the drug is homogenized by passing it through a die (homogenizer to die).
- the gel thus obtained can be divided into tubes.
- Each application will consist of a hazelnut of approximately 1 g.
- a gel intended for transdermal administration of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) - N, N-diisopropyl-2-naphthalenamine was prepared, according to the procedure described in Example 4 except that was used poloxamer Lutrol ® F 127 (BASF) as gelling agent.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002370581A CA2370581A1 (fr) | 1999-04-26 | 2000-04-26 | Nouvelles compositions pharmaceutiques comprenant des derives de 8-isoxazole-2-aminotetralines |
AU43044/00A AU4304400A (en) | 1999-04-26 | 2000-04-26 | Novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives |
EP00922748A EP1173173A1 (fr) | 1999-04-26 | 2000-04-26 | Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines |
US10/069,804 US6685959B1 (en) | 1999-04-26 | 2000-04-26 | Pharmaceutical compositions comprising 2-isoxazoles-8-aminotetralin derivatives |
JP2000613435A JP2002542290A (ja) | 1999-04-26 | 2000-04-26 | 8−イソオキサゾール−2−アミノテトラリン誘導体を含有する新規医薬組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR99/05268 | 1999-04-26 | ||
FR9905268A FR2792529B1 (fr) | 1999-04-26 | 1999-04-26 | Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000064444A1 true WO2000064444A1 (fr) | 2000-11-02 |
Family
ID=9544866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/001099 WO2000064444A1 (fr) | 1999-04-26 | 2000-04-26 | Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines |
Country Status (7)
Country | Link |
---|---|
US (1) | US6685959B1 (fr) |
EP (1) | EP1173173A1 (fr) |
JP (1) | JP2002542290A (fr) |
AU (1) | AU4304400A (fr) |
CA (1) | CA2370581A1 (fr) |
FR (1) | FR2792529B1 (fr) |
WO (1) | WO2000064444A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
DE10066158B4 (de) * | 2000-08-24 | 2007-08-09 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms |
DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
EP1386604A1 (fr) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Systeme d'administation transdermique amélioré |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
US8246980B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
DK1426049T3 (da) * | 2002-12-02 | 2005-08-22 | Sanol Arznei Schwarz Gmbh | Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom |
DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
US9532946B2 (en) | 2012-11-20 | 2017-01-03 | Intervet Inc. | Manufacturing of semi-plastic pharmaceutical dosage units |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990015047A1 (fr) * | 1989-05-31 | 1990-12-13 | The Upjohn Company | Derives de 2-aminotetraline therapeutiquement utiles |
EP0498590A1 (fr) * | 1991-02-08 | 1992-08-12 | Eli Lilly And Company | 2-Amino-1,2,3,4-tétrahydronaphthalènes substitués au noyau |
EP0565274A1 (fr) * | 1992-03-25 | 1993-10-13 | Eli Lilly And Company | Agonistes 5-HT1A pour l'amélioration de la mémoire à court terme et/ou de la capacité d'apprentissage |
EP0579507A1 (fr) * | 1992-07-17 | 1994-01-19 | Eli Lilly And Company | Dérivés de l'isoxazole pour le traitement du syndrome des intestins irritables |
WO1999013879A1 (fr) * | 1997-09-17 | 1999-03-25 | Sanofi-Synthelabo | Compositions pharmaceutiques contenant un inhibiteur de la monoamine oxydase et leur application en therapeutique |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8815180D0 (en) * | 1988-06-25 | 1988-08-03 | Beecham Group Plc | Compositions |
IL114715A (en) * | 1989-02-27 | 1997-01-10 | Lilly Co Eli | Intermediate compounds for ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes and 3-aminochromanes |
ES2100211T3 (es) * | 1990-08-15 | 1997-06-16 | Lilly Co Eli | 2-amino-1,2,3,4-tetrahidronaftalenos, 3-aminocromanos y 3-aminotiocromanos sustituidos en el anillo. |
JP3599766B2 (ja) * | 1993-12-01 | 2004-12-08 | 久光製薬株式会社 | 貼付製剤 |
-
1999
- 1999-04-26 FR FR9905268A patent/FR2792529B1/fr not_active Expired - Fee Related
-
2000
- 2000-04-26 JP JP2000613435A patent/JP2002542290A/ja active Pending
- 2000-04-26 AU AU43044/00A patent/AU4304400A/en not_active Abandoned
- 2000-04-26 CA CA002370581A patent/CA2370581A1/fr not_active Abandoned
- 2000-04-26 US US10/069,804 patent/US6685959B1/en not_active Expired - Fee Related
- 2000-04-26 WO PCT/FR2000/001099 patent/WO2000064444A1/fr active Search and Examination
- 2000-04-26 EP EP00922748A patent/EP1173173A1/fr not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990015047A1 (fr) * | 1989-05-31 | 1990-12-13 | The Upjohn Company | Derives de 2-aminotetraline therapeutiquement utiles |
EP0498590A1 (fr) * | 1991-02-08 | 1992-08-12 | Eli Lilly And Company | 2-Amino-1,2,3,4-tétrahydronaphthalènes substitués au noyau |
EP0565274A1 (fr) * | 1992-03-25 | 1993-10-13 | Eli Lilly And Company | Agonistes 5-HT1A pour l'amélioration de la mémoire à court terme et/ou de la capacité d'apprentissage |
EP0579507A1 (fr) * | 1992-07-17 | 1994-01-19 | Eli Lilly And Company | Dérivés de l'isoxazole pour le traitement du syndrome des intestins irritables |
WO1999013879A1 (fr) * | 1997-09-17 | 1999-03-25 | Sanofi-Synthelabo | Compositions pharmaceutiques contenant un inhibiteur de la monoamine oxydase et leur application en therapeutique |
Also Published As
Publication number | Publication date |
---|---|
JP2002542290A (ja) | 2002-12-10 |
EP1173173A1 (fr) | 2002-01-23 |
CA2370581A1 (fr) | 2000-11-02 |
FR2792529A1 (fr) | 2000-10-27 |
FR2792529B1 (fr) | 2001-09-28 |
US6685959B1 (en) | 2004-02-03 |
AU4304400A (en) | 2000-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0757911B1 (fr) | Nouvelles formulations galéniques du fénofibrate et leurs applications | |
CA2033499C (fr) | Methode d'administration de l'ibuprofene par voie percutanee dans un gel hydroalcoolique | |
EP0503988B1 (fr) | Compositions pour le traitement des onychomycoses | |
EP0385846B1 (fr) | Composition pharmaceutique à libération prolongée d'acide valproîque | |
WO2000064444A1 (fr) | Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines | |
CA2231342C (fr) | Composition pharmaceutique pour administration par voie orale | |
FR2742989A1 (fr) | Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs | |
FR2514642A1 (fr) | Compositions pharmaceutiques a liberation retardee | |
FR2732223A1 (fr) | Composition pharmaceutique pour administration transdermique | |
FR2848112A1 (fr) | Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations | |
FR2801507A1 (fr) | Dispositif transdermique auto-adhesif comprenant un reservoir et une matrice contenant le meme principe actif, son procede de preparation et ses utilisations | |
FR2628971A1 (fr) | Forme d'administration solide, a desagregation rapide, du diclofenac | |
WO1998011881A1 (fr) | Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques | |
CA2374606C (fr) | Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives | |
JPH0840880A (ja) | 軟ゼラチンカプセル剤中のケトプロフエン溶液に基づく医薬製剤およびその調製法 | |
EP0359625B1 (fr) | Dispositif auto-adhésif d'administration d'un principe actif par voie percutanée | |
EP0117164B1 (fr) | Médicament à libération programmée associant l'acide acétylsalicylique à la dihydroergotamine | |
EP1732525B1 (fr) | Patch d'amorolfine pour le traitement de l'onychomycose | |
TWI308873B (fr) | ||
EP0966276B1 (fr) | Utilisation d'agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants | |
FR2741532A1 (fr) | Nouvelles compositions pharmaceutiques a action antimigraineuse et leur mode de preparation | |
WO2004014360A2 (fr) | Compositions pharmaceutiques destinees au traitement de l'incontinence urinaire | |
EP0412877A1 (fr) | Nouvelle forme galénique orale améliorant la biodisponibilité | |
WO1994018962A1 (fr) | Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine | |
FR2469180A1 (fr) | Medicament a base de derives de l'acide apovincaminique pour le traitement des maladies de la peau associees a une proliferation pathologique des cellules telles que le psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 613435 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2370581 Country of ref document: CA Ref country code: CA Ref document number: 2370581 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000922748 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000922748 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10069804 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000922748 Country of ref document: EP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |